Trial Profile
A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (iNHL)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 29 Feb 2024
Price :
$35
*
At a glance
- Drugs Axicabtagene ciloleucel (Primary) ; Cyclophosphamide; Fludarabine
- Indications Follicular lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma
- Focus Registrational; Therapeutic Use
- Acronyms ZUMA-5
- Sponsors Kite Pharma
- 29 Feb 2024 Results from ELARA and ZUMA-5, comparing efficacy and safety outcomes in r/r FL using matching-adjusted indirect comparison methodspublished in the Leukemia and Lymphoma
- 12 Dec 2023 Results reporting updated outcomes from ZUMA-5 after a median follow-up of greater than 4 years presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 12 Dec 2023 Results of a retrospective intra patient 4-year analysis efficacy of axi-cel versus most recent prior line of SOC therapy among patients with R/R FL presented at the 65th American Society of Hematology Annual Meeting and Exposition